- HIV drug sales rescue GSK's second quarter
- Hikma 'sixth largest US generics firm' following Roxane buy from Boehringer
- Can India's Syngene best WuXi?
- Novartis talks up potential blockbusters
- INTERVIEW: Yabao sees niche as China's asset appetite swells
- The EMA at 20: Guido Rasi looks at how the EU regulatory landscape might change over the next decade